Skip to main content
SpringerLink
Log in

Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors

  • Clinical Experience With Positive Inotropic Substances
  • Published:
Basic Research in Cardiology Aims and scope Submit manuscript

Summary

In the first part of this presentation, data is reported on the hemodynamic effects of forskolin given to patients with dilated cardiomyopathy in a concentration of 3 µg/kg/min and 4 µg/kg/min. At the lower dosage, forskolin had no effect on dP/dtmax, cardiac index, ejection fraction, or myocardial oxygen consumption. With small dosages of dobutamine, however, an increase of all four parameters has been observed in the same group of patients. Systemic vascular resistance and left ventricular enddiastolic pressure fell with forskolin given at the lower concentration. Forskolin administered at a dosage of 4 µg/kg/min induced an increase in dP/dtmax by 19% and a 16% rise in heart rate. However, these changes were associated with symptomatic flush syndromes. Therefore, forskolin may serve as a vasodilating substance in lower concentrations, but cannot be used as a positive inotropic compound because of the subjective symptoms.

In the second part, a study is reported in which an anti-ischemic effect of the phosphodiesterase inhibitor enoximone was observed in patients with proven significant coronary heart disease. With respect to the hemodynamic parameters, the most striking findings were the decreases in left ventricular enddiastolic pressure and systemic vascular resistance. Furthermore, when left ventricular stroke work index was plotted as a function of the left ventricular enddiastolic pressure, enoximone shifted the left ventricular function curve to the left. Therefore, the anti-ischemic effect of enoximone may not only be due to a reduction in preload and afterload but may rather reflect an effect on diastolic compliance. Studies with intracoronary injections of enoximone and animal experiments support this hypothesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kariya T, Wille LJ, Dage RC (1982) Biochemical studies of mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol 4:509

    Article  PubMed  CAS  Google Scholar 

  2. Endoh M, Yamashita S, Taira N (1981) Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharm Exp Ther 216:220–224

    Google Scholar 

  3. Honerjager P, Schafer-Korting M, Reiter M (1981) Involvement of cyclic AMP in the direct inotropic action of amrinone: biochemical and functional evidence. Naunyn Schmiedeberg’s Arch Pharmacol 318:112–120

    CAS  Google Scholar 

  4. Kramer W, Thormann J, Schlepper M (1981) Effects of the new cardiotonic agent AR-L115 in normal hearts and loss of its effectivity by the Ca++ antagonist verapamil. Eur Heart J 2 (Suppl A):56

    Google Scholar 

  5. Kramer W, Thormann J, Schlepper M, Bittner C, Zrenner E (1981) Aktivitätsprofil von AR-L 115 BS bei therapierefraktärer kongestiver Kardiomyopathie (CC) und Herzgesunden (HG): Wirkungsverlust durch Ca2+-Antagonisten. Verh Dtsch Ges Inn Med 87:446–450

    Google Scholar 

  6. Bristow MR, Strosberg AM, Ginsburg R (1983) Forskolin activation of human myocardial adenylate cyclase. Circulation 69 (Suppl III):60

    Google Scholar 

  7. Ginsburg R, Strosberg AM, Bristow MR, Montgomery W (1983) Inotropic potential of forskolin in failing human hearts. Circulation 69 (Suppl III):373

    Google Scholar 

  8. Linderer E, Metzger H (1985) The positive inotropic and smooth muscle relaxing effects of forskolin by direct activation of adenylate cyclase. In: Rupp RH, de Souza NJ, Dohadwalla AN (eds) Proceedings of the International Symposium on Forskolin: Its chemical biological and medical potential. Bombay, January, pp 83–101

  9. Lele RD, Kamdar NB, Popat N, Nair KG (1985) Study of forskolin with the nuclear stethoscope. In: Rupp RH, de Souza NJ, Dohadwalla AN (eds) Proceedings of the International Symposium on Forskolin: Its chemical biological and medical potential. Bombay, January, pp 115–127

  10. Linderer T, Biamino G (1985) Hemodynamic and cardiac metabolic effects of forskolin. In: Rupp RH, de Souza NJ, Dohadwalla AN (eds) Proceedings of the International Symposium on Forskolin: Its chemical biological and medical potential. Bombay, January, pp 103–115

  11. Kramer W, Thormann J, Kindler M, Schlepper M (1987) Forskolin’s effects on left ventricular function in dilated cardiomyopathy. Arzneim-Forschg/Drug Res 37 (I)/3:364–367

    CAS  Google Scholar 

  12. Bretschneider HJ, Cott La, Hellige G, Hensel I, Kettler D, Martl J (1971) A new hemodynamic parameter consisting of 5 additive determinants of estimation of the O2-consumption of the left ventricle. Proceedings of the International Congress of Physiological Sciences, pp 98–111

  13. Baller D, Bretschneider HJ, Hellige G (1981) A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol 76:163–181

    Article  PubMed  CAS  Google Scholar 

  14. Gaasch WH, Batlle WE, Oboler AA, Banas JS, Levine HJ (1972) Left ventricular stress and compliance in man. Circulation 45:746–751

    PubMed  CAS  Google Scholar 

  15. Amin DK, Shah PK, Hulse S, Shellock FG, Swan HJC (1984) Myocardial metabolic and haemodynamic effects of intravenous MDL 17,043, a new cardiotonic drug, in patients with chronic severe heart failure. Am Heart J 108:1285

    Article  PubMed  CAS  Google Scholar 

  16. Arbogast R, Brandt C, Haegele KD, Fincker JL, Schechter PJ (1983) Haemodynamic effects of MDL 17,043, a new cardiotonic agent in patients with congestive heart failure: comparison with sodium nitroprusside. J Cardiovasc Pharmacol 5:998

    Article  PubMed  CAS  Google Scholar 

  17. Benotti J, Grossman W, Braunwald E et al. (1980) Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 62:28

    PubMed  CAS  Google Scholar 

  18. Grosse R, Strain M, Greenberg M et al. (1986) Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 7:1107

    Article  Google Scholar 

  19. Jentzer J, LeJemtel T, Sonnenblick E, Kirk E (1981) Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. Am J Cardiol 48:75–83

    Article  PubMed  CAS  Google Scholar 

  20. Likoff MJ, Martin JL, Andrews V, Weber KT (1983) Long-term therapy with the cardiotonic agent MDL 17,043, in chronic cardiac failure. Circulation 68 (Suppl III):III-373

    Google Scholar 

  21. Neuzner J, Mitrovic V, Kornecki P, Schlepper M (1987) Enoximone (MDL 17,043): Hämodynamische Effekte bei dilatativer Cardiomyopathie (DCM). Z Kardiol 76 (Suppl):69

    Google Scholar 

  22. Uretsky BF, Generalovich T, Reddy RS, Spangenberg RB, Follansbee WP (1983) The acute haemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation 67:823

    PubMed  CAS  Google Scholar 

  23. Weber KT, Jain MC, Janicki JS (1985) Enoximone (MDL 17,043) in the long-term treatment of chronic cardiac failure of mild to moderate severity. Circulation 72 (Suppl III):III-202

  24. Cardenas LM, Vidaurri DA (1979) Estudio de los efectos hemodynamicos de differentes dosis de un nuevo intropico: la amrinona. Arch Inst Cardiol Mex 49:961–968

    PubMed  CAS  Google Scholar 

  25. Firth BG, Ratner AV, Grassman ED, Winniford MD, Nocod P, Hillis LD (1984) Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. Am J Cardiol 54:1331–1336

    Article  PubMed  CAS  Google Scholar 

  26. Hermiller JB, Leithe ME, Magorien RD, Unverferth DV, Leier CV (1984) Amrinone in severe congestive heart failure: another look at an intriguing new cardiotonic drug. J Pharmac Exp Ther 228:319–326

    CAS  Google Scholar 

  27. Wilmshurst PT, Thompson DS, Jenkins BS, Coltart DJ, Webb-Peploe MM (1983) Hemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J 49:77–82

    PubMed  CAS  Google Scholar 

  28. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Coltart DJ, Webb-Peploe MM (1984) Comparison of the effect of amrinone and sodium nitroprusside on hemodynamics, contractility and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J 52:38–48

    PubMed  CAS  Google Scholar 

  29. Thormann J, Kramer W, Kindler M, Kremer P, Schlepper M (1987) Bestimmung der Wirkkomponenten von Amrinon durch kontinuierliche Analyse der Druck/Volumen-Beziehungen; Anwendung der Conductance (Volumen-) Katheter-Technik und der schnellen Laständerung durch Ballon-Okklusion der Vena cava inferior. Z Kardiol 76:530–540

    PubMed  CAS  Google Scholar 

  30. Baan J, Van der Velde ET, De Bruin HG, Smeenk GJ, Koops J, Van Duk AD, Temmerman D, Senden J, Buis B (1984) Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 70:812–823

    PubMed  CAS  Google Scholar 

  31. Mitrovic V, Neuzner J, Dieterich HA, Schlepper M (1988) Hemodynamic effects of an i.v.- and p.o. single dose of enoximone in patients with impaired LV-function. Eur Heart J 9 (Suppl 1)

  32. Schliep HJ, Harting I (1986) Effect of ismazole and reference compounds on hemodynamic parameters in anesthetized dogs. Naunyn-Schmiedeberg’s Arch Pharmacol [Suppl] 334:R36

    Google Scholar 

  33. Herrmann HC, Ruddy TD, Dec W, Strauss HW, Boucher CA, Fifer MA (1987) Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analyis. J Am Coll Cardiol 9:1117–1123

    Article  PubMed  CAS  Google Scholar 

  34. Thormann J, Kramer W, Schlepper M (1982) Hemodynamic and myocardial energetic changes induced by the new cardiotonic agent, AR-L 115, in patients with coronary artery disease. Am Heart J 104:1294–1302

    Article  PubMed  CAS  Google Scholar 

  35. Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M (1983) Effects of AR-L 115 BS (Sulmazol), a new cardiotonic agent, in coronary artery disease: improved ventricular wall motion, increased pump function and abolition of pacing-induced ischemia. J Am Coll Cardiol 2:332–337

    Article  PubMed  CAS  Google Scholar 

  36. Rooke GA, Feigl EO (1982) Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circul Res 50:273

    CAS  Google Scholar 

  37. Mitrovic V, Schlepper M, Neuzner J, Bahavar H, Volz M, Dieterich HA (1988) Hämodynamische, antiischämische, metabolische und neurohumorale Effekte von Enoximon (MDL 17,043) bei Patienten mit koronarer Herzkrankheit. Z Kardiol 77:660–667

    PubMed  CAS  Google Scholar 

  38. Mitrovic V, Bahaver H, Neuzner J, Dieterich HA, Schlepper M (1989) Antiischämische Wirksamkeit nach Einzelgabe von 150 mg Enoximon bei Patienten mit koronarer Herzkrankheit. Z Kardiol (in press)

  39. Thormann J, Kremer P, Mitrovic V, Neuzner J, Bahavar H, Schlepper M (1989) Effects of enoximone in coronary artery disease: increased pump function, improved ventricular wall motion, and abolition of pacing-induced myocardial ischemia. J Appl Cardiol 4:152–167

    Google Scholar 

  40. Berwing K, Schlepper M, Kremer P, Bahavar H (1986) Assessment of myocardial perfusion abnormalities in patients with coronary heart disease by intracoronary injection of a new echo contrast agent. Circulation 74:(Suppl II)475

    Google Scholar 

  41. Berwing K, Schlepper M, Kremer P, Bahavar H (1989) Beurteilung myokardialer Perfusionsstörungen bei Patienten mit koronarer Herzkrankheit mittels intrakoronarer Injektion eines neuen Echo-Kontrastmittels. In: Grube E (Hrsg) Farb-Doppler- und Kontrast-Echokardiographie. Thieme, Stuttgart New York, S 323–335

    Google Scholar 

  42. Taira N (1983) Amrinone. Nippon Rinsho 41:15

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kerckhoff-Klinik of the Max-Planck Society, Bad Nauheim, FRG

    M. Schlepper, J. Thormann & V. Mitrovic

Authors
  1. M. Schlepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Thormann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Mitrovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlepper, M., Thormann, J. & Mitrovic, V. Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors. Basic Res Cardiol 84, 197–212 (1989). https://doi.org/10.1007/BF02650360

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02650360

Keywords

Search

Navigation